Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (Dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women

Journal of Sexual Medicine

Volumn 11, Issue 7, 2014, Pages 1766-1785

  Labrie, Fernand ^a   Archer, David ^b   Bouchard, Céline ^c   Fortier, Michel ^c   Cusan, Leonello ^a   Gomez, José Luis ^a   Girard, Ginette ^d   Baron, Mira ^e   Ayotte, Normand ^f   Moreau, Michèle ^g   Dubé, Robert ^h   Côté, Isabelle ^a   Labrie, Claude ^a   Lavoie, Lyne ^a   Gilbert, Lucy ⁱ   Martel, Céline ^a   Balser, John ^j  

^a Endoceutics Inc   (Canada)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Clinique de Recherche en Sante des Femmes   (Canada)

^d Diex Recherche Inc   (Canada)

^e Rapid Medical Research   (United States)

^f Clinique Gynecologique   (Canada)

^g CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ ROYAL VICTORIA HOSPITAL   (Canada)

^j Veristat Inc   (United States)

more..

Author keywords

Androgens; Dehydroepiandrosterone (DHEA); Female sexual dysfunction; Intracrinology; Low arousal; Low desire; Nerve fibers; Vagina

Indexed keywords

PLACEBO; PRASTERONE; ANDROGEN; ESTROGEN; SUPPOSITORY;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPAREUNIA; FEMALE; FEMALE SEXUAL DYSFUNCTION; FEMALE SEXUAL FUNCTION INDEX; HUMAN; INTIMACY; MAJOR CLINICAL STUDY; MENOPAUSE SPECIFIC QUALITY OF LIFE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORGASM; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; TREATMENT DURATION; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINAL LUBRICATION; AGED; AROUSAL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; INNERVATION; INTRAVAGINAL DRUG ADMINISTRATION; MENOPAUSE; MIDDLE AGED; NERVE FIBER; QUESTIONNAIRE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SUPPOSITORY; VAGINA; VAGINAL DISEASES;

ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ANDROGENS; AROUSAL; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; DYSPAREUNIA; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NERVE FIBERS; ORGASM; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SUPPOSITORIES; VAGINA; VAGINAL DISEASES;

EID: 84903814438     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12517     Document Type: Article

References (102)

1. Béjin A. Sexual pleasures, dysfunctions, fantaisies, and satisfaction. In: Spira A, Bajos N, eds. Sexual behaviour and AIDS. Aldershot, England: Avebury; 1994:163-171. ed.
2. Kontula O, Haavio-Mannila E. Sexual pleasures. Enhancement of sex life in Finland, 1971-1992. Aldershot, England: Dartmouth; 1995.
3. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006;24:2815-2821.
4. Nathorst-Boos J, von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992;34:97-101.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-544.
6. Osborn M, Hawton K, Gath D. Sexual dysfunction among middle aged women in the community. Br Med J (Clin Res Ed) 1988;296:959-962.
7. Hallstrom T. Sexuality in the climacteric. Clin Obstet Gynaecol 1977;4:227-239.
8. Hallstrom T, Samuelsson S. Changes in women's sexual desire in middle life: The longitudinal study of women in Gothenburg. Arch Sex Behav 1990;19:259-268.
9. Bancroft J, Cawood EH. Androgens and the menopause; A study of 40-60-year-old women. Clin Endocrinol (Oxf) 1996;45:577-587.
10. Avis NE, Stellato R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning? Menopause 2000;7:297-309.
11. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76:456-460.
12. Dennerstein L, Smith AM, Morse CA, Burger HG. Sexuality and the menopause. J Psychosom Obstet Gynaecol 1994;15:59-66.
13. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008;168:1441-1449.
14. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006;13:46-56.
15. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-922.
16. American Psychiatric Association. DSM-IV: Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
17. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-118.
18. Labrie F, Luu-The V, Bélanger A, Lin S-X, Simard J, Labrie C. Is DHEA a hormone? Starling review. J Endocrinol 2005;187:169-196.
19. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Corrigendum to: Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;112:169.
20. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178-194.
21. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160.
22. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409.
23. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 2008;11:181-191.
24. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-236.
25. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-1352.
26. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000;57:149-153, discussion 55-6.
27. Tuiten A, van Honk J, Verbaten R, Laan E, Everaerd W, Stam H. Can sublingual testosterone increase subjective and physiological measures of laboratory-induced sexual arousal? Arch Gen Psychiatry 2002;59:465-466.
28. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-398.
29. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847-856.
30. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 study. Menopause 2006;13:770-779.
31. Davis SR, Tran J. Testosterone influences libido and well being in women. Trends Endocrinol Metab 2001;12:33-37.
32. Hulter B, Lundberg PO. Sexual function in women with hypothalamo-pituitary disorders. Arch Sex Behav 1994;23:171-183.
33. Basson R. Hormones and sexuality: Current complexities and future directions. Maturitas 2007;57:66-70.
34. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70:1124-1131.
35. Labrie F, Martel C, Balser J. Wide distribution of the serum DHEA and sex steroids levels in postmenopausal women-Role of the ovary? Menopause 2011;18:30-43.
36. Labrie F. DHEA after menopause-Sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Manag 2010;19:14-24.
37. Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women's sexual dysfunction. Menopause 2010;17:962-971.
38. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-96.
39. Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 2008;93:801-808.
40. Genazzani AR, Pluchino N. DHEA therapy in postmenopausal women: The need to move forward beyond the lack of evidence. Climacteric 2010;13:314-316.
41. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin S-X, Pelletier G. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-182.
42. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-3505.
43. Labrie F. Dehydroepiandrosterone (DHEA) as potential hormone replacement therapy. Réf Gynécol Obstét 2001;8:317-322.
44. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, Basile G, Nicita-Mauro V, Cucinotta D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457-461.
45. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737-743.
46. Gonzalez M, Viafara G, Caba F, Molina E. Sexual function, menopause and hormone replacement therapy (HRT). Maturitas 2004;48:411-420.
47. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284-1290.
48. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-931.
49. Pelletier G, Ouellet J, Martel C, Labrie F. Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal wall thickness and innervation. J Sex Med 2012;9:2525-2533.
50. ter Kuile MM, Brauer M, Laan E. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS): Psychometric properties within a Dutch population. J Sex Marital Ther 2006;32:289-304.
51. Kaplan HS. Hypoactive sexual desire. J Sex Marital Ther 1977;3:3-9.
52. Lief HI. Inhibited sexual desire. Med Aspects Hum Sex 1977;7:94-95.
53. Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch Sex Behav 2009;39:221-239.
54. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005;2(3 suppl):154-165.
55. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77(4 suppl):S42-48.
56. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1-20.
57. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW. Definitions of women's sexual dysfunction reconsidered: Advocating expansion and revision. J Psychosom Obstet Gynaecol 2003;24:221-229.
58. Brotto LA, Heiman JR, Tolman DL. Narratives of desire in mid-age women with and without arousal difficulties. J Sex Res 2009;46:387-398.
59. Cawood EH, Bancroft J. Steroid hormones, the menopause, sexuality and well-being of women. Psychol Med 1996;26:925-936.
60. Garde K, Lunde I. Female sexual behaviour. A study in a random sample of 40-year-old women. Maturitas 1980;2:225-240.
61. Cain VS, Johannes CB, Avis NE, Mohr B, Schocken M, Skurnick J, Ory M. Sexual functioning and practices in a multi-ethnic study of midlife women: Baseline results from SWAN. J Sex Res 2003;40:266-276.
62. Giles KR, McCabe MP. Conceptualizing women's sexual function: Linear vs. circular models of sexual response. J Sex Med 2009;6:2761-2771.
63. McCall K, Meston C. Cues resulting in desire for sexual activity in women. J Sex Med 2006;3:838-852.
64. McCall K, Meston C. Differences between pre- and postmenopausal women in cues for sexual desire. J Sex Med 2007;4:364-371.
65. Laan E, Both S. What makes women experience desire? Fem Psychol 2008;18:505-514.
66. Prause N, Janssen E, Hetrick WP. Attention and emotional responses to sexual stimuli and their relationship to sexual desire. Arch Sex Behav 2008;37:934-949.
67. Singer B, Toates EM. Sexual motivation. J Sex Res 1987;23:481-501.
68. Both S, Everaerd W, Laan E. Modulation of spinal reflexes by aversive and sexually appetitive stimuli. Psychophysiology 2003;40:174-183.
69. Both S, Spiering M, Everaerd W, Laan E. Sexual behavior and responsiveness to sexual stimuli following laboratory-induced sexual arousal. J Sex Res 2004;41:242-258.
70. Everaerd W, Laan E. Desire for passion: Energetics of sexual response. J Sex Marital Ther 1995;21:255-263.
71. Laan E, Everaerd J. Determinants of sexual arousal: Psychophysiological theory and data. Annu Rev Sex Res 1995;6:32-76.
72. Laan E, Everaerd W, van der Velde J, Geer JH. Determinants of subjective experience of sexual arousal in women: Feedback from genital arousal and erotic stimulus content. Psychophysiology 1995;32:444-451.
73. Derogatis LR, Conklin-Powers B. Psychological assessment measures of female sexual functioning in clinical trials. Int J Impot Res 1998;10(2 suppl):S111-116.
74. Talakoub L, Munarriz R, Hoag L, Gioia M, Flaherty E, Goldstein I. Epidemiological characteristics of 250 women with sexual dysfunction who presented for initial evaluation. J Sex Marital Ther 2002;28(1 suppl):217-224.
75. Rosen RC, Taylor JF, Leiblum SR, Bachmann GA. Prevalence of sexual dysfunction in women: Results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther 1993;19:171-188.
76. Hartmann U, Heiser K, Ruffer-Hesse C, Kloth G. Female sexual desire disorders: Subtypes, classification, personality factors and new directions for treatment. World J Urol 2002;20:79-88.
77. Sand M, Fisher WA. Women's endorsement of models of female sexual response: The nurses' sexuality study. J Sex Med 2007;4:708-719.
78. Segraves R, Balon R, Clayton A. Proposal for changes in diagnostic criteria for sexual dysfunctions. J Sex Med 2007;4:567-580.
79. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: A survey of Western European women. J Sex Med 2006;3:212-222.
80. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. J Urol 2003;170:2333-2338.
81. Dennerstein L, Lehert P. Modeling mid-aged women's sexual functioning: A prospective, population-based study. J Sex Marital Ther 2004;30:173-183.
82. Graham CA, Sanders SA, Milhausen RR, McBride KR. Turning on and turning off: A focus group study of the factors that affect women's sexual arousal. Arch Sex Behav 2004;33:527-538.
83. Sidi H, Naing L, Midin M, Nik Jaafar NR. The female sexual response cycle: Do Malaysian women conform to the circular model? J Sex Med 2008;5:2359-2366.
84. Carvalheira AA, Brotto LA, Leal I. Women's motivations for sex: Exploring the diagnostic and statistical manual, fourth edition, text revision criteria for hypoactive sexual desire and female sexual arousal disorders. J Sex Med 2010;7:1454-1463.
85. Graham CA. The DSM diagnostic criteria for female sexual arousal disorder. Arch Sex Behav 2010;39:240-255.
86. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. In: Brunner/Mazel, ed. The new sex therapy. Vol. II. New York; 1979:257.
87. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6:1549-1560.
88. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008;112:970-978.
89. Hayes RD, Bennett CM, Fairley CK, Dennerstein L. What can prevalence studies tell us about female sexual difficulty and dysfunction? J Sex Med 2006;3:589-595.
90. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
91. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003;29:39-46.
92. Labrie F. Drug insight: Breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007;3:584-593.
93. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 2004;292:2243-2248.
94. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6:138-146.
95. Labrie F. DHEA, important source of sex steroids in men and even more in women. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff D, eds. Neuroendocrinology, the normal neuroendocrine system, progress in brain research. Elsevier; 2010:97-148.
96. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897-906.
97. Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 2013;16:205-213.
98. Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez JL, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182-188.
99. Pessina MA, Hoyt RF Jr, Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology 2006;147:61-69.
100. Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201-215.
101. Pelletier G, Ouellet J, Martel C, Labrie F. Androgenic Action of Dehydroepiandrosterone (DHEA) on Nerve Density in the Ovariectomized Rat Vagina. J Sex Med 2013;10:1908-1914.
102. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause 2012;19:630-635.